Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

American journal of hematology·2026
Same author

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Cancer·2026
Same author

Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic Approaches.

Blood cancer discovery·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same journal

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same journal

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

American journal of hematology·2026
Same journal

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

American journal of hematology·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

Guillermo Garcia-Manero1

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

American Journal of Hematology
|July 4, 2026
PubMed
Summary
This summary is machine-generated.

Myelodysplastic syndromes (MDS) are myeloid disorders with cytopenias and risk of AML. Diagnosis involves bone marrow examination, with prognosis and therapy guided by risk stratification systems like IPSS-R and IPSS-M.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jul 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders.
  • Characterized by peripheral blood cytopenias and a risk of transformation to acute myelogenous leukemia (AML).
  • MDS predominantly affects older males and individuals with prior cytotoxic therapy exposure.

Purpose of the Study:

  • To provide a comprehensive overview of myelodysplastic syndromes (MDS).
  • To detail diagnostic criteria, prognostic scoring systems, and risk-adapted therapeutic strategies.
  • To highlight recent therapeutic advancements and the role of allogeneic stem cell transplantation (alloSCT).

Main Methods:

  • Diagnosis relies on morphological assessment of bone marrow aspirates and biopsies.
  • Karyotype, flow cytometry, and molecular genetics complement diagnosis and refinement.
  • Prognosis is determined using scoring systems like the Revised International Prognostic Scoring System (IPSS-R) and molecular IPSS-M (IPSS-M).

Main Results:

  • Therapeutic selection is based on risk, transfusion needs, blast percentage, cytogenetics, mutational profiles, comorbidities, and prior hypomethylating agent (HMA) exposure.
  • Treatment goals differ for lower-risk (reduce transfusions, delay progression) versus higher-risk patients (prolong survival).
  • Recent approvals include luspatercept, oral decitabine/cedazuridine, and imetelstat for specific MDS subtypes.

Conclusions:

  • Allogeneic stem cell transplantation (alloSCT) remains the only curative option for MDS.
  • Therapeutic strategies must be individualized based on patient-specific risk factors and disease characteristics.
  • Further research is needed for effective treatments in progressive or refractory MDS, especially after HMA failure.